Ondansetron Basi (Ondansetron)

Ondansetron Basi is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting: helps maintain patient comfort during radiotherapy.
• Post‑operative nausea and vomiting: lowers the incidence of nausea after surgical procedures.
• Pregnancy‑associated nausea (off‑label): may be considered when benefits outweigh risks, under specialist guidance.
• Hyper‑emesis gravidarum (off‑label): used in severe cases resistant to first‑line therapy.

• Ondansetron selectively blocks serotonin (5‑HT3) receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents serotonin‑mediated stimulation of the vomiting centre, thereby reducing nausea and vomiting triggered by chemotherapy, radiation, surgery or other emetogenic stimuli.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel movement reduction.
• Diarrhoea: loose stools in a minority of patients.
• Fatigue: general tiredness reported.
• Dizziness: transient light‑headedness.
• Injection site pain (if administered parenterally): mild discomfort at the site.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe hypersensitivity: rash, itching, swelling or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes in susceptible individuals.
• Neuroleptic malignant‑like reactions: very rare, characterized by fever and rigidity.
• Vision changes: blurred vision or visual disturbances.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities or electrolyte disturbances.

• Cardiac monitoring: obtain baseline ECG in patients at risk for QT prolongation.
• Electrolyte assessment: correct potassium, magnesium and calcium before initiation.
• Hepatic impairment: adjust dosing in severe liver disease.
• Drug interactions: review concomitant medications that affect QT interval.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medicines that influence cardiac rhythm or serotonin pathways.

Major Interactions (Avoid)

• Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.
• Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation.
• Serotonergic drugs (e.g., tramadol, linezolid, SSRIs): raise potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure.
• Diuretics causing electrolyte loss: heighten QT‑prolongation risk.
• Other anti‑emetics (e.g., granisetron, dolasetron): overlapping mechanisms, monitor efficacy.
• Oral contraceptives: possible slight reduction in hormonal efficacy.